Please sign in so that we can notify you about a reply
Indications/Uses
Indicated for the treatment of ischaemic heart disease - angina pectoris, sequelae of infarction.
Dosage/Direction for Use
Angimax: 40 to 60 mg is given daily by mouth in divided doses. To be taken after meals or as prescribed by the physician.
Angimax MR: Two (2) tablets a day. To be taken after meals or as prescribed by the physician.
Angimax MR: Two (2) tablets a day. To be taken after meals or as prescribed by the physician.
Administration
Should be taken with food.
Contraindications
No further studies have been made. Hypersensitivity to the product itself brought about by other components used in the product itself.
Special Precautions
The attending physician should be informed of the following conditions: Pregnancy, Trimetazidine dihydrochloride should be avoided particularly during the first trimester of pregnancy except when absolutely required. However, there is insufficient evidence to recommend the use of trimetazidine in pregnancy. Animal studies do not reveal any teratogenic effect.
Nursing Mothers, there is no information on the secretion of trimetazidine into breast milk. However, breastfeeding should be discontinued if the use of trimetazidine is considered essential.
Pediatric use, there is no experience with trimetazidine in children.
Impaired Renal and Hepatic Function, no dosage adjustments are required in patients with impaired renal and hepatic function.
Nursing Mothers, there is no information on the secretion of trimetazidine into breast milk. However, breastfeeding should be discontinued if the use of trimetazidine is considered essential.
Pediatric use, there is no experience with trimetazidine in children.
Impaired Renal and Hepatic Function, no dosage adjustments are required in patients with impaired renal and hepatic function.
Use In Pregnancy & Lactation
Pregnancy, Trimetazidine dihydrochloride should be avoided particularly during the first trimester of pregnancy except when absolutely required. However, there is insufficient evidence to recommend the use of trimetazidine in pregnancy. Animal studies do not reveal any teratogenic effect.
Nursing Mothers, there is no information on the secretion of trimetazidine into breast milk. However, breastfeeding should be discontinued if the use of trimetazidine is considered essential.
Nursing Mothers, there is no information on the secretion of trimetazidine into breast milk. However, breastfeeding should be discontinued if the use of trimetazidine is considered essential.
Adverse Reactions
Gastric discomfort, nausea, headache, vertigo.
Drug Interactions
No drug interactions have so far been reported. In particular, no interactions of trimetazidine with beta-blockers, calcium antagonists, nitrates, heparin, hypolipidemic agents or digitalis have been reported. No further studies have been made regarding the concomitant use of Trimetazidine dihydrochloride (Angimax/Angimax MR) with MAOIs, it is advised that Trimetazidine dihydrochloride (Angimax/Angimax MR) must not be used or coadministered with MAOIs.
Storage
Store at temperatures not exceeding 30°C.
Action
A metabolic approach to this drug best describes its property as an ANTI-ANGINAL drug. First described as First Cytoprotective anti-ischaemic agent, acts by directly counteracting all the major metabolic disorders occurring within the cell. Includes 3 metabolic activities, limitation of the intracellular acidosis, correction of the disturbances on ion membrane exchange and prevention of excessive production of free radicals. With these effects it then reduces the side effects of an impaired left ventricular function, excessive peripheral vasodilation. Second, so unique, as its properties, it belongs to a new class of compounds that displays an anti-ischaemic effect without inducing haemodynamic changes and improves ischaemic myocardium.
MedsGo Class
Anti-Anginal Drugs
Features
Brand
Angimax MR
Full Details
Dosage Strength
35mg
Drug Ingredients
- Trimetazidine
Drug Packaging
Modified-Release Tablet 1's
Generic Name
Trimetazidine diHcl
Dosage Form
Modified-Release Tablet
Registration Number
DR-XY37311
Drug Classification
Prescription Drug (RX)